Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer;Grundlagen der Tumorentstehung und die Bedeutung Humaner Papillomaviren (HPV) bei Kopf-Hals-Karzinomen

Laryngo- Rhino- Otologie

Volumn 91, Issue SUPPL. 1, 2012, Pages

  Wittekindt, C ^a   Wagner, S ^a   Mayer, C S ^a   Klussmann J P ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

carcinogenesis; head and neck cancer; human papillomavirus; molecular markers; prognosis

Indexed keywords

ARTICLE; DISEASE COURSE; HEAD AND NECK CANCER; PRIORITY JOURNAL; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; COMBINED MODALITY THERAPY; DNA DAMAGE; DNA, VIRAL; GENE SILENCING; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; HEAD AND NECK NEOPLASMS; HUMANS; ONCOGENE PROTEINS, VIRAL; OROPHARYNGEAL NEOPLASMS; OTORHINOLARYNGOLOGIC NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS;

EID: 84859347891     PISSN: 09358943     EISSN: 14388685     Source Type: Journal    
DOI: 10.1055/s-0031-1297241     Document Type: Article

References (194)

1. Parkin D M, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55 74 108
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57 43 66
3. Sankaranarayanan R, Masuyer E, Swaminathan R et al. Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res: 1998; 18 4779 4786 (Pubitemid 29042060)
4. Sturgis E M, Cinciripini P M. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer: 2007; 110 1429 1435 (Pubitemid 47463055)
5. Hammarstedt L, Dahlstrand H, Lindquist D et al. The incidence of tonsillar cancer in Sweden is increasing. Acta Otolaryngol: 2007; 127 988 992 (Pubitemid 47345807)
6. Shiboski C H, Schmidt B L, Jordan R C. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer: 2005; 103 1843 1849 (Pubitemid 40563256)
7. Blomberg M, Nielsen A, Munk C et al. Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int J Cancer: 2011; 129 733 741
8. De Souza D L, De Camargo Cancela M, Perez M M et al. Trends in the incidence of oral cavity and oropharyngeal cancers in Spain. Head Neck: 2001
9. Sturgis E M, Ang K K. The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms? J Natl Compr Canc Netw: 2011; 9 665 673
10. Mork J, Moller B, Dahl T et al. Time trends in pharyngeal cancer incidence in Norway 1981-2005: a subsite analysis based on a reabstraction and recoding of registered cases. Cancer Causes Control: 2010; 21 1397 1405
11. Chaturvedi A K, Engels E A, Anderson W F et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol: 2008; 26 612 619 (Pubitemid 351264356)
12. Adelstein D J, Ridge J A, Gillison M I et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck: 2009; 31 1393 1422
13. D'souza G, Kreimer A R, Viscidi R et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med: 2007; 356 1944 1956 (Pubitemid 46740304)
14. Klussmann J P, Weissenborn S J, Wieland U et al. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer: 2001; 92 2875 2884
15. D'souza G, Agrawal Y, Halpern J et al. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis: 2009; 199 1263 1269
16. Loning T, Ikenberg H, Becker J et al. Analysis of oral papillomas, leukoplakias, and invasive carcinomas for human papillomavirus type related DNA. J Invest Dermatol: 1985; 84 417 420 (Pubitemid 15056667)
17. Marur S, D'souza G, Westra W H et al. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol: 2010; 11 781 789
18. Nasman A, Attner P, Hammarstedt L et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer: 2009; 125 362 366
19. Klussmann J P, Dinh S, Guntinas-Lichius O et al. HPV-associated tonsillar cancer. An update. HNO: 2004; 52 208 218 (Pubitemid 38374140)
20. Klussmann J P, Preuss S F, Speel E J. Human papillomavirus and cancer of the oropharynx. Molecular interaction and clinical implications. HNO: 2009; 57 113 122
21. Kreimer A R, Clifford G M, Boyle P et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev: 2005; 14 467 475 (Pubitemid 40270113)
22. Ribeiro K B, Levi J E, Pawlita M et al. Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int J Epidemiol: 2011; 40 489 502
23. Kutler D I, Auerbach A D, Satagopan J et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg: 2003; 129 106 112 (Pubitemid 36070885)
24. Wynder E L, Bross I J. Aetiological factors in mouth cancer; an approach to its prevention. Br Med J: 1957; 1 1137 1143
25. Franceschi S, Levi F, La Vecchia C et al. Comparison of the effect of smoking and alcohol drinking between oral and pharyngeal cancer. Int J Cancer: 1999; 83 1 4 (Pubitemid 29409467)
26. Talamini R, Bosetti C, La Vecchia C et al. Combined effect of tobacco and alcohol on laryngeal cancer risk: a case-control study. Cancer Causes Control: 2002; 13 957 964 (Pubitemid 36169479)
27. Pai S I, Westra W H. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol: 2009; 4 49 70
28. Llewellyn C D, Linklater K, Bell J et al. Squamous cell carcinoma of the oral cavity in patients aged 45 years and under: a descriptive analysis of 116 cases diagnosed in the South East of England from 1990 to 1997. Oral Oncol. 2003; 39 106 114
29. Koch W M, Lango M, Sewell D et al. Head and neck cancer in nonsmokers: a distinct clinical and molecular entity. Laryngoscope: 1999; 109 1544 1551 (Pubitemid 29477216)
30. Castellsague X, Quintana M J, Martinez M C et al. The role of type of tobacco and type of alcoholic beverage in oral carcinogenesis. Int J Cancer: 2004; 108 741 749 (Pubitemid 38076406)
31. Zhang Z F, Morgenstern H, Spitz M R et al. Environmental tobacco smoking, mutagen sensitivity, and head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev: 2000; 9 1043 1049
32. Schlecht N F, Franco E L, Pintos J et al. Effect of smoking cessation and tobacco type on the risk of cancers of the upper aero-digestive tract in Brazil. Epidemiology: 1999; 10 412 418 (Pubitemid 29288240)
33. Gillison M L, Koch W M, Capone RB. et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst: 2000; 92 709 720 (Pubitemid 30365531)
34. Wiest T, Schwarz E, Enders C et al. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene: 2002; 21 1510 1517 (Pubitemid 34226138)
35. Braakhuis B J, Snijders P J, Keune W J et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst: 2004; 96 998 1006 (Pubitemid 39162642)
36. Termine N, Giovannelli L, Matranga D et al. Oral human papillomavirus infection in women with cervical HPV infection: new data from an Italian cohort and a metanalysis of the literature. Oral Oncol: 2011; 47 244 250
37. Rintala M A, Grenman S E, Jarvenkyla M E et al. High-risk types of human papillomavirus (HPV) DNA in oral and genital mucosa of infants during their first 3 years of life: experience from the Finnish HPV Family Study. Clin Infect Dis: 2005; 41 1728 1733 (Pubitemid 41759856)
38. Do Sacramento P R, Babeto E, Colombo J et al. The prevalence of human papillomavirus in the oropharynx in healthy individuals in a Brazilian population. J Med Virol: 2006; 78 614 618
39. Klingenberg B, Hafkamp H C, Haesevoets A et al. p16 INK4A overexpression is frequently detected in tumour-free tonsil tissue without association with HPV. Histopathology: 2010; 56 957 967
40. Smith E M, Ritchie J M, Summersgill K F et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer: 2004; 108 766 772 (Pubitemid 38076410)
41. Kreimer A R, Alberg A J, Daniel R et al. Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis: 2004; 189 686 698 (Pubitemid 38270923)
42. Mork J, Lie A K, Glattre E. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med: 2001; 344 1125 1131 (Pubitemid 32285233)
43. Heck J E, Berthiller J, Vaccarella S et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol: 2010; 39 166 181
44. Gillison M L, D'souza G, Westra W et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst: 2008; 100 407 420 (Pubitemid 351480511)
45. Syrjanen S. The role of human papillomavirus infection in head and neck cancers. Ann Oncol: 2010; 21 07 vii243 vii245
46. Kjaer S K, Engholm G, Dahl C et al. Case-control study of risk factors for cervical squamous cell neoplasia in Denmark. IV: role of smoking habits. Eur J Cancer Prev: 1996; 5 359 365 (Pubitemid 27006994)
47. Giuliano A R, Sedjo R L, Roe D J et al. Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). Cancer Causes Control: 2002; 13 839 846 (Pubitemid 35305203)
48. Ndisang D, Khan A, Lorenzato F et al. The cellular transcription factor Brn-3a and the smoking-related substance nicotine interact to regulate the activity of the HPV URR in the cervix. Oncogene: 2010; 29 2701 2711
49. Sinha P, Logan H L, Mendenhall W M. Human papillomavirus, smoking, and head and neck cancer. Am J Otolaryngol: 2011
50. Applebaum K M, Furniss C S, Zeka A et al. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst: 2007; 99 1801 1810 (Pubitemid 351767210)
51. Smith E M, Rubenstein L M, Haugen T H et al. Tobacco and alcohol use increases the risk of both HPV-associated and HPV-independent head and neck cancers. Cancer Causes Control: 2010; 21 1369 1378
52. Herrero R, Castellsague X, Pawlita M et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst: 2003; 95 1772 1783 (Pubitemid 38008900)
53. Hafkamp H C, Manni J J, Haesevoets A et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer: 2008; 122 2656 2664 (Pubitemid 351631366)
54. Albers A E, Hoffmann T K, Klussmann J P et al. Prophylactic and therapeutic vaccines against human papilloma virus. HNO: 2010; 58 778 790
55. Pathirana D, Hillemanns P, Petry K U et al. Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia. Vaccine: 2009; 27 4551 4559
56. Robert-Koch-Institut Impfungen gegen humane Papillomaviren (HPV) für Mädchen und Frauen von 12-17 Jahren - Empfehlung und Begründung. Epid Bull: 2007; 12 7
57. Robert-Koch-Institut Impfungen gegen HPV - Aktuelle Bewertung der STIKO. Epid Bull: 2009; 32 9
58. Hildesheim A, Herrero R, Wacholder S et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA: 2007; 298 743 753 (Pubitemid 47263157)
59. Schiller J T, Lowy DR. et al. Prospects for cervical cancer prevention by human papillomavirus vaccination. Cancer Res: 2006; 66 10229 10232 (Pubitemid 44799735)
60. Campo M S, Roden R B et al. Papillomavirus prophylactic vaccines: established successes, new approaches. J Virol: 2010; 84 1214 1220
61. Li Y L, Qiu X H, Shen C et al. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors. Oncol Rep: 2010; 24 1323 1329
62. Huang C F, Monie A, Weng W H et al. DNA vaccines for cervical cancer. Am J Transl Res: 2010; 2 75 87
63. Donovan B, Franklin N, Guy R et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis: 2011; 11 39 44
64. Giuliano A R, Palefsky J M, Goldstone S et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med: 2011; 364 401 411
65. Michor F, Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prev Res (Phila): 2010; 3 1361 1364
66. Slebos R J, Yi Y, Ely K et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res: 2006; 12 701 709 (Pubitemid 43259848)
67. Chung C H, Parker J S, Ely K et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res: 2006; 66 8210 8218 (Pubitemid 44299189)
68. Chung C H, Parker J S, Karaca G et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell: 2004; 5 489 500 (Pubitemid 38610250)
69. Hermsen M, Guervos M A, Meijer G et al. New chromosomal regions with high-level amplifications in squamous cell carcinomas of the larynx and pharynx, identified by comparative genomic hybridization. J Pathol: 2001; 194 177 182 (Pubitemid 32519967)
70. Jin C, Jin Y, Wennerberg J et al. Cytogenetic abnormalities in 106 oral squamous cell carcinomas. Cancer Genet Cytogenet: 2006; 164 44 53 (Pubitemid 41820355)
71. Smeets S J, Brakenhoff R H, Ylstra B et al. Genetic classification of oral and oropharyngeal carcinomas identifies subgroups with a different prognosis. Cell Oncol: 2009; 31 291 300
72. Klussmann J P, Mooren J J, Lehnen M et al. Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications. Clin Cancer Res: 2009; 15 1779 1786
73. Slaughter D P, Southwick H W, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer: 1953; 6 963 968
74. Mcgovern S L, Williams M D, Weber R S et al. Three synchronous HPV-associated squamous cell carcinomas of Waldeyer's ring: case report and comparison with Slaughter's model of field cancerization. Head Neck: 2010; 32 1118 1124
75. Mao L, Hong W K, Papadimitrakopoulou V A. Focus on head and neck cancer. Cancer Cell: 2004; 5 311 316 (Pubitemid 38482067)
76. Hogmo A, Munck-Wikland E, Kuylenstierna R et al. Nuclear DNA content and p53 immunostaining in metachronous preneoplastic lesions and subsequent carcinomas of the oral cavity. Head Neck: 1996; 18 433 440 (Pubitemid 26268842)
77. Sudbo J, Lippman S M, Lee J J et al. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med: 2004; 350 1405 1413 (Pubitemid 38419994)
78. Mao L, Lee J S, Fan Y H et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med: 1996; 2 682 685 (Pubitemid 26191956)
79. Rosin M P, Cheng X, Poh C et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res: 2000; 6 357 362 (Pubitemid 30111451)
80. Izzo J G, Papadimitrakopoulou V A, Liu D D et al. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst: 2003; 95 198 205 (Pubitemid 36240632)
81. Mutirangura A, Supiyaphun P, Trirekapan S et al. Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer Res: 1996; 56 3530 3533 (Pubitemid 26251648)
82. Shin D M, Charuruks N, Lippman S M et al. p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev: 2001; 10 603 609 (Pubitemid 32703194)
83. Reed A L, Califano J, Cairns P et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res: 1996; 56 3630 3633 (Pubitemid 26272001)
84. Smeets S J, Braakhuis B J, Abbas S et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene: 2006; 25 2558 2564
85. Smirnova T, Adomako A, Locker J. In vivo invasion of head and neck squamous cell carcinoma cells does not require macrophages. Am J Pathol: 2011; 178 2857 2865
86. Yeudall W A, Miyazaki H, Ensley J F et al. Uncoupling of epidermal growth factor-dependent proliferation and invasion in a model of squamous carcinoma progression. Oral Oncol: 2005; 41 698 708 (Pubitemid 40981110)
87. Fei J, Hong A, Dobbins T A et al. Prognostic significance of vascular endothelial growth factor in squamous cell carcinomas of the tonsil in relation to human papillomavirus status and epidermal growth factor receptor. Ann Surg Oncol: 2009; 16 2908 2917
88. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer: 2010; 10 415 424
89. Qiu W, Schonleben F, Li X et al. Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4. Cancer Lett: 2007; 245 163 170 (Pubitemid 44959352)
90. Bornstein S, White R, Malkoski S et al. Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J Clin Invest: 2009; 119 3408 3419
91. Cohen J, Chen Z, Lu S L et al. Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer. Cancer Res: 2009; 69 3415 3424
92. Nathan C O, Amirghahari N, Abreo F et al. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res: 2004; 10 5820 5827 (Pubitemid 39180961)
93. Pickering B M, Willis A E. The implications of structured 5 untranslated regions on translation and disease. Semin Cell Dev Biol: 2005; 16 39 47 (Pubitemid 40126875)
94. Okami K, Wu L, Riggins G et al. Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res: 1998; 58 509 511 (Pubitemid 28087415)
95. De Villiers E M, Fauquet C, Broker T R et al. Classification of papillomaviruses. Virology: 2004; 324 17 27 (Pubitemid 38737395)
96. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer: 2002; 2 342 350 (Pubitemid 37328947)
97. Petry K U, Scheffel D, Bode U et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer: 1994; 57 836 840 (Pubitemid 24216820)
98. Doorbar J. The papillomavirus life cycle. J Clin Virol: 2005; 32 01 S7 S15 (Pubitemid 40332584)
99. Duensing S, Lee L Y, Duensing A et al. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc Natl Acad Sci USA: 2000; 97 10002 10007
100. Duensing S, Munger K. Human papillomavirus type 16 E7 oncoprotein can induce abnormal centrosome duplication through a mechanism independent of inactivation of retinoblastoma protein family members. J Virol: 2003; 77 12331 12335 (Pubitemid 37339885)
101. Von Knebel Doeberitz M, Bauknecht T, Bartsch D et al. Influence of chromosomal integration on glucocorticoid-regulated transcription of growth-stimulating papillomavirus genes E6 and E7 in cervical carcinoma cells. Proc Natl Acad Sci USA: 1991; 88 1411 1415 (Pubitemid 21916234)
102. Von Knebel Doeberitz M, Oltersdorf T, Schwarz E et al. Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res: 1988; 48 3780 3786
103. Kessis T D, Connolly D C, Hedrick L et al. Expression of HPV16 E6 or E7 increases integration of foreign DNA. Oncogene: 1996; 13 427 431 (Pubitemid 26334876)
104. Romanczuk H, Howley P M. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc Natl Acad Sci USA: 1992; 89 3159 3163
105. Jeon S, Lambert P F et al. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci USA: 1995; 92 1654 1658
106. Luft F, Klaes R, Nees M et al. Detection of integrated papillomavirus sequences by ligation-mediated PCR (DIPS-PCR) and molecular characterization in cervical cancer cells. Int J Cancer: 2001; 92 9 17 (Pubitemid 32187026)
107. Wentzensen N, Ridder R, Klaes R et al. Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions. Oncogene: 2002; 21 419 426 (Pubitemid 34123804)
108. Butel J S. Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcinogenesis: 2000; 21 405 426 (Pubitemid 30137926)
109. Dall K L, Scarpini C G, Roberts I et al. Characterization of naturally occurring HPV16 integration sites isolated from cervical keratinocytes under noncompetitive conditions. Cancer Res: 2008; 68 8249 8259
110. Ferris R L, Martinez I, Sirianni N et al. Human papillomavirus-16 associated squamous cell carcinoma of the head and neck (SCCHN): a natural disease model provides insights into viral carcinogenesis. Eur J Cancer: 2005; 41 807 815 (Pubitemid 40342563)
111. Rampias T, Sasaki C, Weinberger P et al. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst: 2009; 101 412 423
112. Gasco M, Crook T. The p53 network in head and neck cancer. Oral Oncol: 2003; 39 222 231 (Pubitemid 36255688)
113. Hafkamp H C, Speel E J, Haesevoets A et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer: 2003; 107 394 400 (Pubitemid 37266459)
114. Psyrri A, Prezas L, Burtness B. Oropharyngeal cancer. Clin Adv Hematol Oncol: 2008; 6 604 612
115. Dai M, Clifford G M, Le Calvez F et al. Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. Cancer Res: 2004; 64 468 471 (Pubitemid 38120884)
116. Weinberger P M, Yu Z, Kountourakis P et al. Defining molecular phenotypes of human papillomavirus-associated oropharyngeal squamous cell carcinoma: validation of three-class hypothesis. Otolaryngol Head Neck Surg: 2009; 141 382 389
117. Stenner M, Yosef B, Huebbers C U et al. Nuclear translocation of beta-catenin and decreased expression of epithelial cadherin in human papillomavirus-positive tonsillar cancer: an early event in human papillomavirus-related tumour progression? Histopathology: 2011; 58 1117 1126
118. Furusawa J, Zhang H, Vural E et al. Distinct epigenetic profiling in head and neck squamous cell carcinoma stem cells. Otolaryngol Head Neck Surg: 2011; 144 900 909
119. Sartor M A, Dolinoy D C, Jones T R et al. Genome-wide methylation and expression differences in HPV(+) and HPV() squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics: 2011; 6 777 787
120. Park I S, Chang X, Loyo M et al. Characterization of the methylation patterns in human papillomavirus type 16 viral DNA in head and neck cancers. Cancer Prev Res (Phila): 2011; 4 207 217
121. Cervigne N K, Reis P P, Machado J et al. Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Hum Mol Genet: 2009; 18 4818 4829
122. Liu X, Jiang L, Wang A. MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines. Cancer Lett: 2009; 286 217 222
123. Liu X, Yu J, Jiang L et al. MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genomics Proteomics: 2009; 6 131 139
124. Yu Z W, Zhong L P, Ji T et al. MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol: 2010; 46 317 322
125. Lajer C B, Nielsen F C, Friis-Hansen L. Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study. Br J Cancer: 2011; 104 830 840
126. Wald A I, Hoskins E E, Wells S I et al. Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus. Head Neck: 2011; 33 504 512
127. Holleman A, Chung I, Olsen R R et al. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene: 2011
128. Nagel R, Le Sage C, Diosdado B et al. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res: 2008; 68 5795 5802
129. Liu C J, Kao S Y, Tu H F. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis: 2010; 16 360 364
130. Park N J, Zhou H, Elashoff D et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res: 2009; 15 5473 5477
131. Wollenberg B. Implication of stem cells in the biology and therapy of head and neck cancer. Laryngorhinootologie: 2011; 90 01 S110 S119
132. Garrity T, Pandit R, Wright M A et al. Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells. Int J Cancer: 1997; 73 663 669 (Pubitemid 127483061)
133. Pandit R, Lathers D M, Beal N M et al. CD34+ immune suppressive cells in the peripheral blood of patients with head and neck cancer. Ann Otol Rhinol Laryngol: 2000; 109 749 754 (Pubitemid 30637030)
134. Young M R, Petruzzelli G J, Kolesiak K et al. Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34(+) progenitor cells. Hum Immunol: 2001; 62 332 341 (Pubitemid 32298975)
135. Tabor M H, Clay M R, Owen J H et al. Head and neck cancer stem cells: the side population. Laryngoscope: 2011; 121 527 533
136. Martens J E, Arends J, Van Der Linden P J et al. Cytokeratin 17 and p63 are markers of the HPV target cell, the cervical stem cell. Anticancer Res: 2004; 24 771 775 (Pubitemid 38625020)
137. Regenbrecht C R, Lehrach H, Adjaye J. Stemming cancer: functional genomics of cancer stem cells in solid tumors. Stem Cell Rev: 2008; 4 319 328
138. Wittekindt C, Wagner S, Klussmann J P. HPV-associated head and neck cancer: The basics of molecular and translational research. HNO: 2011
139. Cuzick J, Szarewski A, Cubie H et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet: 2003; 362 1871 1876 (Pubitemid 37518501)
140. Schiffman M, Castle P E, Jeronimo J et al. Human papillomavirus and cervical cancer. Lancet: 2007; 370 890 907 (Pubitemid 47371147)
141. Raffle A E, Alden B, Quinn M et al. Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented. BMJ: 2003; 326 901
142. Wallin K L, Wiklund F, Angstrom T et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med: 1999; 341 1633 1638
143. Wentzensen N, Vinokurova S, Von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res: 2004; 64 3878 3884 (Pubitemid 38697299)
144. Andrews E, Shores C, Hayes D N et al. Concurrent human papillomavirus-associated tonsillar carcinoma in 2 couples. J Infect Dis: 2009; 200 882 887
145. Giraldo P, Goncalves A K, Pereira S A et al. Human papillomavirus in the oral mucosa of women with genital human papillomavirus lesions. Eur J Obstet Gynecol Reprod Biol: 2006; 126 104 106
146. Hemminki K, Dong C. Cancer in husbands of cervical cancer patients. Epidemiology: 2000; 11 347 349 (Pubitemid 30228208)
147. Roberts J N, Buck C B, Thompson C D et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med: 2007; 13 857 861 (Pubitemid 47038188)
148. Begum S, Cao D, Gillison M et al. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res: 2005; 11 5694 5699 (Pubitemid 41170292)
149. Kim J S, Crooks H, Foxworth A et al. Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors. Mol Cancer Ther: 2002; 1 1355 1359
150. Sant M, Aareleid T, Berrino F et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. Ann Oncol: 2003; 14 05 v61 v118 (Pubitemid 46417464)
151. Guntinas-Lichius O, Wendt T, Buentzel J et al. Head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database. J Cancer Res Clin Oncol: 2010; 136 55 63
152. Weber A, Schmid K W, Tannapfel A et al. Changes in the TNM classification of head and neck tumors. Pathologe: 2010; 31 339 343
153. Preuss S F, Klussmann J P, Wittekindt C et al. Long-term results of the combined modality therapy for advanced cervical metastatic head and neck squamous cell carcinoma. Eur J Surg Oncol: 2007; 33 358 363 (Pubitemid 46488670)
154. Preuss S F, Cramer K, Klussmann J P et al. Transoral laser surgery for laryngeal cancer: outcome, complications and prognostic factors in 275 patients. Eur J Surg Oncol: 2009; 35 235 240
155. Psychogios G, Waldfahrer F, Bozzato A et al. Evaluation of the revised TNM classification in advanced laryngeal cancer. Eur Arch Otorhinolaryngol: 2010; 267 117 121
156. Hall S F, Groome P A, Irish J et al. TNM-based stage groupings in head and neck cancer: application in cancer of the hypopharynx. Head Neck: 2009; 31 1 8
157. Kreppel M, Eich H T, Kubler A et al. Prognostic value of the sixth edition of the UICC's TNM classification and stage grouping for oral cancer. J Surg Oncol: 2010; 102 443 449
158. Groome P A, Schulze K M, Mackillop W J et al. A comparison of published head and neck stage groupings in carcinomas of the tonsillar region. Cancer: 2001; 92 1484 1494 (Pubitemid 32947833)
159. Byers R M, Bland K I, Borlase B et al. The prognostic and therapeutic value of frozen section determinations in the surgical treatment of squamous carcinoma of the head and neck. Am J Surg: 1978; 136 525 528 (Pubitemid 9027667)
160. Guillemaud J P, Patel R S, Goldstein D P et al. Prognostic impact of intraoperative microscopic cut-through on frozen section in oral cavity squamous cell carcinoma. J Otolaryngol Head Neck Surg: 2010; 39 370 377
161. Ganly I, Patel S, Shah J. Early stage squamous cell cancer of the oral tongue-clinicopathologic features affecting outcome. Cancer: 2011
162. Mohit-Tabatabai M A, Sobel H J, Rush B F et al. Relation of thickness of floor of mouth stage I and II cancers to regional metastasis. Am J Surg: 1986; 152 351 353 (Pubitemid 16001461)
163. Jeremic B, Milicic B. Pretreatment prognostic factors of survival in patients with locally advanced nonmetastatic squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy. Am J Clin Oncol: 2009; 32 163 168
164. Ang K K, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med: 2010; 363 24 35
165. De Graeff A, De Leeuw J R, Ros W J et al. Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. Eur J Cancer: 2001; 37 332 339 (Pubitemid 32182321)
166. Poeta M L, Manola J, Goldwasser M A et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med: 2007; 357 2552 2561 (Pubitemid 350294222)
167. Brennan J A, Mao L, Hruban R H et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med: 1995; 332 429 435
168. Sardi I, Franchi A, Ferriero G et al. Prediction of recurrence by microsatellite analysis in head and neck cancer. Genes Chromosomes Cancer: 2000; 29 201 206
169. Martone T, Gillio-Tos A, De Marco L et al. Association between hypermethylated tumor and paired surgical margins in head and neck squamous cell carcinomas. Clin Cancer Res: 2007; 13 5089 5094 (Pubitemid 47502075)
170. Nathan C O, Liu L, Li B D et al. Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer. Oncogene: 1997; 15 579 584 (Pubitemid 27384735)
171. Harden S V, Thomas D C, Benoit N et al. Real-time gap ligase chain reaction: a rapid semiquantitative assay for detecting p53 mutation at low levels in surgical margins and lymph nodes from resected lung and head and neck tumors. Clin Cancer Res: 2004; 10 2379 2385 (Pubitemid 38445696)
172. Fakhry C, Westra W H, Li S et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst: 2008; 100 261 269 (Pubitemid 351480538)
173. Pang E, Delic N C, Hong A et al. Radiosensitization of oropharyngeal squamous cell carcinoma cells by human papillomavirus 16 oncoprotein E6*I. Int J Radiat Oncol Biol Phys: 2011; 79 860 865
174. Fischer C A, Kampmann M, Zlobec I et al. p16 expression in oropharyngeal cancer: its impact on staging and prognosis compared with the conventional clinical staging parameters. Ann Oncol: 2010; 21 1961 1966
175. Straetmans J M, Olthof N, Mooren J J et al. Human papillomavirus reduces the prognostic value of nodal involvement in tonsillar squamous cell carcinomas. Laryngoscope: 2009; 119 1951 1957
176. Fischer C A, Zlobec I, Green E et al. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer: 2010; 126 1256 1262
177. Licitra L, Perrone F, Bossi P et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol: 2006; 24 5630 5636 (Pubitemid 46631302)
178. Hafkamp H C, Mooren J J, Claessen S M et al. P21 Cip1/WAF1 expression is strongly associated with HPV-positive tonsillar carcinoma and a favorable prognosis. Mod Pathol: 2009; 22 686 698
179. Preuss S F, Weinell A, Molitor M et al. Nuclear survivin expression is associated with HPV-independent carcinogenesis and is an indicator of poor prognosis in oropharyngeal cancer. Br J Cancer: 2008; 98 627 632 (Pubitemid 351214523)
180. Ang K K, Berkey B A, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res: 2002; 62 7350 7356 (Pubitemid 36025259)
181. Kumar B, Cordell K G, Lee J S et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol: 2008; 26 3128 3137
182. Reimers N, Kasper H U, Weissenborn S J et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer: 2007; 120 1731 1738 (Pubitemid 46399359)
183. Sok J C, Coppelli F M, Thomas S M et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res: 2006; 12 5064 5073 (Pubitemid 44453332)
184. Hama T, Yuza Y, Saito Y et al. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist: 2009; 14 900 908
185. Nakata Y, Uzawa N, Takahashi K I et al. EGFR gene copy number alteration is a better prognostic indicator than protein overexpression in oral tongue squamous cell carcinomas. Eur J Cancer: 2011
186. Sheu J J, Hua C H, Wan L et al. Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res: 2009; 69 2568 2576
187. Knudsen B S, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev: 2008; 18 87 96 (Pubitemid 351694452)
188. Smeets S J, Hesselink A T, Speel E J et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer: 2007; 121 2465 2472 (Pubitemid 350022416)
189. Bonner J A, Harari P M, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med: 2006; 354 567 578 (Pubitemid 43209104)
190. Vermorken J B, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med: 2008; 359 1116 1127
191. Huang S, Armstrong E A, Benavente S et al. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res: 2004; 64 5355 5362 (Pubitemid 39006556)
192. Stewart J S, Cohen E E, Licitra L et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol: 2009; 27 1864 1871
193. Abidoye O O, Cohen E E, Wong S J et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol: 2006; 24 297S
194. Punt C J, Nagy A, Douillard J Y et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet: 2002; 360 671 677 (Pubitemid 35232335)